|
Market Closed -
Other stock markets
|
After hours 20:59:59 | |||
| 36.16 EUR | +1.69% |
|
35.88 | -0.79% |
| 01:03pm | Study: Bayer's Finerenone slows progression of chronic kidney disease | RE |
| 12:50pm | Bayer Announces Phase III FIND-CKD Results For KERENDIA In Non-Diabetic Chronic Kidney Disease | CI |
Main competitors
| Change | 5d. change | 1 months change | 3 months change | Varia. Jan 1. | 1-year change | 3-years change | 5-years change | 10-years change | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
 | +1.69% | -4.44% | -3.32% | -3.32% | -2.30% | +42.81% | -31.27% | -31.33% | -59.53% | 40.61B | |
| +0.55% | +0.41% | +16.89% | +12.74% | +5.28% | +47.74% | +155.79% | +460.05% | +1,406.15% | 1,003B | |
| +2.02% | +0.85% | +3.82% | -5.11% | +12.48% | +51.92% | +48.29% | +40.25% | +102.83% | 549B | |
| +1.02% | +3.93% | +9.16% | -3.79% | -0.55% | +21.29% | +66.02% | +102.23% | +249.58% | 397B | |
| +0.22% | -0.55% | +3.35% | -8.84% | -0.34% | +22.42% | +11.71% | +2.25% | +26.68% | 328B | |
| +2.24% | +0.89% | +2.56% | -8.15% | +0.49% | +28.72% | +17.96% | +72.04% | +243.10% | 282B | |
| +1.85% | -0.24% | +3.64% | -7.60% | +7.65% | +22.84% | +32.01% | +45.62% | +49.34% | 269B | |
| +4.43% | -3.32% | +0.32% | +15.64% | -12.73% | -40.46% | -47.48% | +15.49% | +53.14% | 196B | |
| +1.15% | +3.89% | +7.95% | -7.83% | +6.80% | +21.80% | +60.31% | +47.60% | +119.60% | 187B | |
| -0.02% | -5.18% | -2.66% | -12.86% | +5.23% | +18.47% | +65.82% | +91.55% | +49.92% | 160B | |
| +1.36% | -0.38% | -0.99% | -2.18% | +4.58% | +11.33% | -32.12% | -33.49% | -24.94% | 146B | |
| +1.18% | +0.63% | -0.19% | -8.12% | +6.17% | +19.44% | -12.78% | -11.81% | -21.43% | 116B | |
| +1.15% | -0.25% | +3.95% | -6.50% | -1.44% | +0.22% | +33.87% | +112.85% | +375.55% | 112B | |
| +1.98% | +2.08% | +0.18% | -1.62% | -5.77% | -10.53% | -17.93% | -9.44% | +7.53% | 107B | |
| +1.89% | +1.04% | +1.95% | -8.37% | +6.22% | +29.72% | +41.71% | +14.49% | +6.26% | 102B | |
| -0.17% | -2.44% | -8.38% | -22.58% | -8.36% | +1.38% | +94.64% | +80.76% | +505.13% | 77.84B | |
| -.--% | +1.73% | - | - | - | - | - | - | - | 63.66B | |
| +1.57% | -3.79% | -5.97% | -12.16% | +1.88% | +15.04% | +10.25% | +34.15% | +6.46% | 47.89B | |
| +0.97% | -1.92% | -12.62% | -11.14% | -20.97% | -14.85% | +2.28% | -31.64% | +226.04% | 45.59B | |
| -0.19% | -0.66% | +1.72% | -7.41% | -23.79% | -0.74% | +56.48% | +108.14% | +331.70% | 40.54B | |
| Average | +1.14% | -1.30% | +1.12% | -5.75% | -1.02% | +15.19% | +29.24% | +58.41% | +192.27% | 213.56B | |
| Weighted average by Cap. | +1.05% | -0.43% | +6.07% | -1.31% | +2.92% | +26.93% | +58.96% | +142.78% | +426.96% |
- Stock Market
- Equities
- BAYN Stock
- Sector Bayer AG
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition